KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Capital Expenditures (2016 - 2025)

Edwards Lifesciences has reported Capital Expenditures over the past 17 years, most recently at $97.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $97.4 million for Q4 2025, up 95.58% from a year ago — trailing twelve months through Dec 2025 was $260.2 million (up 3.09% YoY), and the annual figure for FY2025 was $260.2 million, up 3.09%.
  • Capital Expenditures for Q4 2025 was $97.4 million at Edwards Lifesciences, up from $57.5 million in the prior quarter.
  • Over the last five years, Capital Expenditures for EW hit a ceiling of $106.0 million in Q1 2021 and a floor of $43.1 million in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $61.1 million (2021), compared with a mean of $66.8 million.
  • Biggest five-year swings in Capital Expenditures: plummeted 43.6% in 2024 and later surged 95.58% in 2025.
  • Edwards Lifesciences' Capital Expenditures stood at $89.8 million in 2021, then fell by 23.27% to $68.9 million in 2022, then increased by 28.16% to $88.3 million in 2023, then plummeted by 43.6% to $49.8 million in 2024, then surged by 95.58% to $97.4 million in 2025.
  • The last three reported values for Capital Expenditures were $97.4 million (Q4 2025), $57.5 million (Q3 2025), and $49.3 million (Q2 2025) per Business Quant data.